Please try another search
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson’s disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Timothy R. Pearson | 56 | 2023 | Independent Director |
David L. Lucchino | 55 | - | Director |
Ram Aiyar | 46 | 2020 | CEO, President & Director |
Rachel Meyers | 60 | 2023 | Independent Director |
Nessan Bermingham | 51 | - | Co-Founder & Independent Chairman of the Board |
Ali Behbahani | 48 | - | Independent Director |
Jean-Francois Formela | 67 | - | Co-Founder & Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review